This Article Full Text Full Text (PDF) A correction has been published Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Artaza, J. N. Articles by Gonzalez-Cadavid, N. F. Search for Related Content PubMed PubMed Citation Articles by Artaza, J. N. Articles by Gonzalez-Cadavid, N. F.

Myostatin Inhibits Myogenesis and Promotes Adipogenesis in C3H 10T(1/2) Mesenchymal Multipotent Cells

Division of Endocrinology Metabolism and Molecular Medicine (J.N.A., S.B., S.R.-P., R.S., N.F.G.-C.), RCMI DNA Molecular Core, Charles R. Drew University of Medicine and Science, Los Angeles, California 90059; Department of Urology (T.R.M., N.F.G.-C.), University of California, Los Angeles School of Medicine, LABioMed Research Institute at Harbor-UCLA Medical Center, Torrance, California 90502; and School of Biological and Molecular Sciences (N.P.G., M.M.F.), Oxford Brookes University, Headington Campus, Oxford OX3 0BP, United Kingdom

Address all correspondence and requests for reprints to: Jorge N. Artaza, Ph.D., Division of Endocrinology, Metabolism, and Molecular Medicine, Charles R. Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, California 90059. E-mail: joartaza{at}cdrewu.edu.

Inactivating mutations of the mammalian myostatin gene are associated with increased muscle mass and decreased fat mass; conversely, myostatin transgenic mice that overexpress myostatin in the skeletal muscle have decreased muscle mass and increased fat mass. We investigated the effects of recombinant myostatin protein and antimyostatin antibody on myogenic and adipogenic differentiation of mesenchymal multipotent cells. Accordingly, 10T(1/2) cells were incubated with 5'-azacytidine for 3 d to induce differentiation and then treated with a recombinant protein for myostatin (Mst) carboxy terminal 113 amino acids or a polyclonal anti-Mst antibody for 3, 7, and 14 d. Cells were also cotransfected with a Mst cDNA plasmid expressing the full-length 375-amino acid protein (pcDNA-Mst375) and the silencer RNAs for either Mst (pSil-Mst) or a random sequence (pSil-RS) for 3 or 7 d, and Mst expression was determined. Adipogenesis was evaluated by quantitative image analysis of fat cells before and after oil-red-O staining, immunocytochemistry of adiponectin, and Western blot for CCAAT/enhancer binding protein-. Myogenesis was estimated by quantitative image analysis-immunocytochemistry for MyoD (Myo differentiation protein), myogenin, and myosin heavy chain type II, or by Western blot for myogenin. 5'-azacytidine-mediated differentiation induced endogenous full-length Mst expression. Recombinant Mst carboxy terminal 113 amino acids inhibited both early and late markers of myogenesis and stimulated both early and late markers of adipogenesis, whereas the antibody against Mst exerted the reverse effects. Myogenin levels at 7 d after transfection of pcDNA-Mst375 were reduced as expected and elevated by pSil-Mst, which blocked efficiently Mst375 expression. In conclusion, myostatin promotes the differentiation of multipotent mesenchymal cells into the adipogenic lineage and inhibits myogenesis.

This article has been cited by other articles:

				J. Tong, M. J. Zhu, K. R. Underwood, B. W. Hess, S. P. Ford, and M. Du AMP-activated protein kinase and adipogenesis in sheep fetal skeletal muscle and 3T3-L1 cells J Anim Sci, June 1, 2008; 86(6): 1296 - 1305. [Abstract] [Full Text] [PDF]

				P Diel, D Baadners, K Schlupmann, M Velders, and J P Schwarz C2C12 myoblastoma cell differentiation and proliferation is stimulated by androgens and associated with a modulation of myostatin and Pax7 expression J. Mol. Endocrinol., May 1, 2008; 40(5): 231 - 241. [Abstract] [Full Text] [PDF]

				W. Guo, J. Flanagan, R. Jasuja, J. Kirkland, L. Jiang, and S. Bhasin The Effects of Myostatin on Adipogenic Differentiation of Human Bone Marrow-derived Mesenchymal Stem Cells Are Mediated through Cross-communication between Smad3 and Wnt/{beta}-Catenin Signaling Pathways J. Biol. Chem., April 4, 2008; 283(14): 9136 - 9145. [Abstract] [Full Text] [PDF]

				J. N Artaza, R. Singh, M. G Ferrini, M. Braga, J. Tsao, and N. F Gonzalez-Cadavid Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/2 cells without affecting their differentiation into myofibroblasts J. Endocrinol., February 1, 2008; 196(2): 235 - 249. [Abstract] [Full Text] [PDF]

				J. N Artaza, S. Reisz-Porszasz, J. S Dow, R. A Kloner, J. Tsao, S. Bhasin, and N. F Gonzalez-Cadavid Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse J. Endocrinol., July 1, 2007; 194(1): 63 - 76. [Abstract] [Full Text] [PDF]

				Y.-C. Liang, J.-Y. Yeh, and B.-R. Ou Effect of maternal myostatin antibody on offspring growth performance and body composition in mice J. Exp. Biol., February 1, 2007; 210(3): 477 - 483. [Abstract] [Full Text] [PDF]

				A M Solomon and P M G Bouloux Modifying muscle mass - the endocrine perspective. J. Endocrinol., November 1, 2006; 191(2): 349 - 360. [Abstract] [Full Text] [PDF]

				B. J. Feldman, R. S. Streeper, R. V. Farese Jr., and K. R. Yamamoto Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effects PNAS, October 17, 2006; 103(42): 15675 - 15680. [Abstract] [Full Text] [PDF]

				L. J. Woodhouse, A. Mukherjee, S. M. Shalet, and S. Ezzat The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults Endocr. Rev., May 1, 2006; 27(3): 287 - 317. [Abstract] [Full Text] [PDF]